3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Johnson, Reed F.
    • Other Affiliation: Emerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Bagci, Ulas
    • Other Affiliation: Center for Research in Computer Vision (CRCV); Department of Electrics Electronics and Computer Science; University of Central Florida
  • Keith, Lauren
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Tang, Xianchun
    • Other Affiliation: Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute; Harvard Medical School
  • Mollura, Daniel J.
    • Other Affiliation: Center for Infectious Disease Imaging; National Institutes of Health Clinical Center
  • Zeitlin, Larry
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Qin, Jing
    • Other Affiliation: Biostatistics Research Branch; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Huzella, Louis
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Bartos, Christopher J.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Bohorova, Natasha
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Bohorov, Ognian
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Goodman, Charles
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Kim, Do H.
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Paulty, Michael H.
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Velasco, Jesus
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Whaley, Kevin J.
    • Other Affiliation: Mapp Biopharmaceutical; Inc.
  • Johnson, Joshua C.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Pettitt, James
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Ork, Britini L.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Solomon, Jeffrey
    • Other Affiliation: Clinical Research Directorate/Clinical Monitoring Research Program; Leidos Biomedical Research; Inc.; Frederick National Laboratory for Cancer Research
  • Oberlander, Nicholas
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Zhu, Quan
    • Other Affiliation: Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute; Harvard Medical School
  • Sun, Jiusong
    • Other Affiliation: Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute; Harvard Medical School
  • Holbrook, Michael R.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Olinger, Gene G.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Baric, Ralph S.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Hensley, Lisa E.
    • Other Affiliation: Integrated Research Facility; National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Jahrling, Peter B.
    • Other Affiliation: Emerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Marasco, Wayne A.
    • Other Affiliation: Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute; Harvard Medical School
Abstract
  • Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1,600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Virology
Journal volume
  • 490
Page start
  • 49
Page end
  • 58
Language
  • English
ISSN
  • 0042-6822
  • 1096-0341
  • 1089-862X

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details PubMedCentral-PMC4769911.pdf 2016 Public Download